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ABSTRACT
Objectives: To assess trends in prescribing practices
of antidiabetic agents and glycaemic control in patients
with type 2 diabetes mellitus (T2DM).
Design: Cross-sectional analysis using yearly clinical
data and antidiabetic treatments prescribed obtained
from an electronic population database.
Setting: Primary healthcare centres, including
the entire population attended by the Institut
Català de la Salut in Catalonia, Spain, from 2007 to
2013.
Participants: Patients aged 31–90 years with a
diagnosis of T2DM.
Results: The number of registered patients with
T2DM in the database was 257 072 in 2007,
increasing up to 343 969 in 2013. The proportion of
patients not pharmacologically treated decreased by
9.7% (95% CI −9.48% to −9.92%), while there was
an increase in the percentage of patients on
monotherapy (4.4% increase; 95% CI 4.16% to
4.64%), combination therapy (2.8% increase; 95% CI
2.58% to 3.02%), and insulin alone or in
combination (increasing 2.5%; 95% CI 2.2% to
2.8%). The use of metformin and dipeptidyl
peptidase-IV inhibitors increased gradually, while
sulfonylureas, glitazones and α-glucosidase
inhibitors decreased. The use of glinides remained
stable, and the use of glucagon-like peptide-1
receptor agonists was still marginal. Regarding
glycaemic control, there were no relevant differences
across years: mean glycated haemoglobin (HbA1c)
value was around 7.2%; the percentage of patients
reaching an HbA1c≤7% target ranged between
52.2% and 55.6%; and those attaining their
individualised target from 72.8% to 75.7%.
Conclusions: Although the proportion of patients
under pharmacological treatment increased
substantially over time and there was an increase in
the use of combination therapies, there have not
been relevant changes in glycaemic control during
the 2007–2013 period in Catalonia.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a highly
prevalent chronic disease at risk of chronic
microvascular and macrovascular complica-
tions when glycaemic control is suboptimal.1
Although diet and lifestyle changes are ini-
tially effective, most patients will need an
oral glucose-lowering agent to better control
blood glucose levels, and most will eventually
need multiple therapies as the disease pro-
gresses.2 The pharmacological armamentar-
ium to treat hyperglycaemia in T2DM has
changed substantially over the past 20 years
with the development of new therapeutic
agents, such as insulin secretagogues (glini-
des), thiazolidinediones, incretins (glucagon-
like peptide-1 receptor agonists (GLP-1ra)
and dipeptidyl peptidase-IV inhibitors (DPP4i)),
sodium-glucose transporter-2 inhibitors, ﬁxed-
dose combinations, and also with the advent of
Strengths and limitations of this study
▪ The main strength of the study is the use of a
large outpatient database that is indicative of the
trends of general practitioners’ practices in a
real-life clinical setting.
▪ However, this was a retrospective study partici-
pant to errors in data recording or missing
values.
▪ We were not able to assess whether the change
in prescribed treatments over time was driven by
patients’ needs and characteristics (eg, prior low
tolerability or effectiveness), and we cannot
therefore claim a causal effect.
▪ We could not assess whether doses of pharma-
cological treatments were appropriately chosen,
and we did not consider data on prescriptions
within the same therapeutic class.
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insulin analogues.3 This, together with changing treat-
ment recommendations advocating for an intense gly-
caemic control in early stages of the disease,4 5 makes
drug choice increasingly challenging, and it has driven
substantial changes in current prescribing practices with
wide variations between countries depending on each
therapeutic class.6–17
General practice databases are a reliable and rich
source of information from the general population, and
therefore a valuable tool to study medical practice in the
community.18 In Catalonia, Spain, such an electronic
general practice database is available for researchers
(Information System for the Development of Research
in Primary Care (SIDIAP)), and it has been previously
used to conduct several observational studies to assess
different aspects of the natural history and treatment of
T2DM in our autonomous region.19–26
In the present study, we aimed to examine prescribing
patterns for antidiabetic treatment in primary care in
Catalonia between 2007 and 2013 using SIDIAP data,
and how changes impacted the degree of attained gly-
caemic control over time.
MATERIALS AND METHODS
Design
This was a cross-sectional, retrospective study using the
SIDIAP database, which started in 2006 and stores data
from electronic medical records. The database contains
anonymised longitudinal patient information obtained
from the electronic clinical records using speciﬁc soft-
ware (Electronic Clinical station in Primary Care, eCAP)
developed by the institution and used since 2001 by all of
the 274 primary care centres pertaining to the Catalan
Health Institute (ICS), which attends 80% of the total
population (about 5.835 million patients) in Catalonia.
Data extraction
Data from patients aged 31 to 90 years with a diagnosis of
T2DM (by means of the International Classiﬁcation of
Diseases, 10th Revision (ICD-10) codes E11 or E14) were
obtained from the SIDIAP database for the years 2007–
2013. Data were extracted for patients for each particular
year. As a dynamic database, new patients enter when a
new diagnosis of T2DM is recorded, and patients are with-
drawn when a death occurs or the patient moves to
another healthcare region not served by the Catalonian
Health Institute. Registered variables included: age;
gender; time since diagnosis; the presence of comorbid-
ities (ICD-10 codes); and the most recent value for each
year of body mass index (BMI) and mean glycated haemo-
globin (HbA1c). Before 1 January 2010, between 50% and
70% of laboratories in Spain expressed HbA1c values
using the Japanese Diabetes Society/Japanese Society for
Clinical Chemistry criteria ( JDS/JCC; normal range 3.9–
5.7%),27 and these values were not converted to the inter-
nationally deﬁned Diabetes Control and Complications
Trial/National Glycohemoglobin Standardization
Program (DCCT/NGSP) calibration criteria (normal
range 4–6%). All values from 1 January 2010 onwards were
expressed using DCCT/NGSP criteria.
The prescribed antidiabetic treatments for each patient
and year were extracted from prescription-invoicing and
pharmacy-invoicing data provided by the Catalan Health
Service (CatSalut), which are incorporated yearly into the
SIDIAP database. Glucose-lowering agents included the
use of insulin and non-insulin antidiabetic drugs (NIADs)
marketed in Spain during the study period, namely met-
formin, sulfonylureas, glinides, glitazones, DPP4i, GLP-1ra
and α-glucosidase inhibitors (AGI). The ﬁrst DPP4i mar-
keted in Spain was sitagliptin (2007) followed by vildaglip-
tin (2007), saxagliptin (2010) and linagliptin (2012). For
GLP-1ra, daily exenatide appeared in 2007, and liraglutide
in 2011. Treatment steps were categorised as non-
pharmacological treatment, an NIAD in monotherapy,
NIADs in combination (2 or more without insulin),
insulin alone or insulin in combination with NIADs.
Statistical analysis
Descriptive analyses by year are presented as mean and
SD for continuous variables, and percentages for cat-
egorical variables. Changes across the study period were
evaluated through the absolute overall increase and the
95% CIs using the normal approximation. We used
three different criteria for adequate glycaemic control:
mean HbA1c≤7%, as widely recommended and
accepted; HbA1c≤8%, as recommended by our institu-
tion during the study period (ICS);28 29 and individua-
lised goals based on age, duration of the disease, and
presence of serious complications or comorbidities, as
proposed by the Red de Grupos de Estudio de la
Diabetes en Atención Primaria de la Salud 2014
(Red-GDPS).30 All statistical calculations were performed
using StataCorp 2009 (Stata Statistical Software: Release
11. College Station, Texas, USA: StataCorp, LP).
RESULTS
Patients’ characteristics
The total number of registered patients with T2DM in
our database was 257 072 in 2007, increasing up to
343 969 in 2013 (a total increase of 86 897 cases) (table 1).
The patients’ mean age did not vary substantially over
the years (overall increase 1.20 years; 95% CI 1.14 to
1.26 years), and nor did the mean BMI or the number
of obese patients (overall decrease 0.08 kg/m2; 95% CI
−0.11 to −0.05 kg/m2; overall 0.043% decrease in obese
patients; 95% CI −0.12% to −0.74%), but we observed a
small progressive increase in the proportion of male
patients (overall increase 2.15%; 95% CI 1.90% to
2.40%), and also a gradual increase in the mean dur-
ation of the disease (overall increase 2.40 years; 95% CI
2.37 to 2.43 years).
Prescribing pattern of antidiabetic drugs
The proportion of patients not receiving antidiabetic
drugs decreased by 9.7% (95% CI −9.48% to −9.92%)
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from 2007 to 2013, while the percentage of patients
receiving pharmacological antidiabetic treatment was
71.9% in 2007, and this proportion increased annually
and was 81.6% in the last year of the study, showing an
overall 9.7% increase over the study period. The propor-
tion of patients receiving each type of therapy across the
time period 2007–2013 is shown in ﬁgure 1. The most
frequent prescription was an NIAD in monotherapy, the
use of which increased 4.4% (95% CI 4.16% to 4.64%)
from 2007 to 2013, followed by NIADs in combination
(increasing 2.8%; 95% CI 2.58% to 3.02%), and insulin
alone or in combination (increasing 2.5%; 95% CI 2.2%
to 2.8%). Among NIADs, the most frequently used
drugs were metformin and sulfonylureas, although the
prescription rate of metformin increased notably across
time (19.5%; 95% CI 19.25% to 19.75%), whereas it
decreased gradually in the case of sulfonylureas (8.20%;
95% CI −7.97% to −8.43%) (ﬁgure 2). As for the use of
the rest of the available options, only the prescription of
DPP4i increased substantially up to 13.2% in 2013 (95%
CI 13.09% to 13.31%), while the use of glitazones, gli-
nides, AGI and GLP-1ra remained low. Glitazones and
AGI prescriptions even decreased with time: glitazones
an overall 2.9% (95% CI −2.82% to −2.98%) and AGI
2.70% (95% CI −2.62% to −2.78%). Finally, glinides
and GLP-1ra only increased slightly over time: 0.8% in
the case of glinides (95% CI 0.69% to 0.91%) and 0.9%
in the case of GLP-1ra (95% CI 0.87% to 0.93%).
Evolution of the degree of glycaemic control
The mean standardised HbA1c value was around 7.2%,
with no clinically relevant differences across years (table 1).
Moreover, the proportion of patients attaining a gly-
caemic target of HbA1c≤7% ranged from 52.2% to
55.6% (overall change 0.29%; 95% CI −0.02% to
0.60%), and the ICS target ≤8% ranged from 77.8% to
79.6% (overall change 0.64%; 95% CI 0.39% to
21.42%), with no clinically relevant changes across years
(table 1). Moreover, the percentage of patients attaining
their individualised HbA1c target ranged increased by
only 1.15% (95% CI 0.88% to 1.42%) (table 1). Finally,
the analysis of the evolution of the attained glycaemic
control according to different HbA1c intervals also
showed that there were no remarkable changes among
years in any case (ﬁgure 3). Of note, the group of
patients who were less likely to achieve the correspond-
ing glycaemic target included those younger than
65 years, without comorbidities, and duration of
T2DM≤15 years (range 50.8–55.1%) (see online
supplementary table S1).
The evolution of the mean Hb1Ac levels according to
each step of treatment and duration of T2DM is shown
in ﬁgure 4 and online supplementary table S2.
Considering all antidiabetic treatments, there was a pro-
gressive worsening of HbA1c levels as the disease dur-
ation increased, but this worsening was in fact only
observed among patients treated with insulin alone or in
combination with NIADs. Conversely, glycaemic values
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in patients not pharmacologically treated or on NIADs
improved as T2DM duration increased, with no substan-
tial differences across the study period.
DISCUSSION
This cross-sectional descriptive study is, to the best of
our knowledge, the ﬁrst to assess trends in the prescrib-
ing practices of antidiabetic drugs in relation to the level
of attained glycaemic control between 2007 and 2013 in
a primary healthcare setting in Spain.
A gradual increase in the prescription of antidiabetic
agents has been previously reported in Spain16 17 and in
studies conducted worldwide throughout the same or
overlapping years as in our study.6–8 10–12 31 32 An increase
in the use of combinations of oral antidiabetic drugs
(OADs) has been consistently observed in several studies
from different countries,6 7 9 11 17 31 but the trends in its
use as monotherapy vary among reports, with some
describing an overall increase over time,11 13 32 and
others a progressive decrease.6 9 31 Moreover, while the
number of prescriptions of insulin in combination with
an OAD has been shown to increase with time,6 7 11 the
use of insulin alone has been reported to remain
stable,17 33 to decrease6 11 31 or even to increase.32
Differences between drug schemes and studies may be
attributable to health policy variations across countries,
local professional expertise, physician’s personal choice,
study setting (eg, hospital vs primary care or insurance
claims vs national database), or inclusion of both patients
with T1DM and T2DM in some cases.
Both an increase in the use of metformin and a
decrease in the use of sulfonylureas have been consist-
ently reported by other groups.6–9 11–13 15 17 31–33 This
decline could be related to the recent recommendation
of cautionary use in the elderly,34 their worse safety
proﬁle, associated weight gain, unclear role in reducing
long-term complications and/or to the availability of
safer new therapeutic options.5 Although a decrease in
glinides and AGIs use has been reported in Spain, Japan
Figure 2 Percentage of patients
having non-insulin antidiabetic
drug prescriptions (alone or in
combination). AGI, α-glucosidase
inhibitors; DPP4i, dipeptidyl
peptidase-IV inhibitors; GLP-1ra,
glucagon-like peptide-1 receptor
agonists; T2DM, type 2 diabetes
mellitus.
Figure 1 Percentage of patients
with T2DM at each step of
antidiabetic treatment. NIAD,
non-insulin antidiabetic drug;
T2DM, type 2 diabetes mellitus.
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and in the UK,11 15 17 33 in our study the number of gli-
nides prescriptions remained stable, which could be
explained by the fact that in spite of their risk of hypo-
glycaemia,5 they are the most used therapeutic class in
patients with chronic kidney disease.25 The decrease in
AGIs might be explained by the high frequency of
gastrointestinal side effects that led to the recommenda-
tion to only use them in people unable to use other oral
glucose-lowering medications.35 The decrease in the use
of glitazones has been consistently documented in
several studies that included data after 2007,8 9 11–13
15 17 31–33 when the ﬁrst regulatory warnings and the
results of a meta-analysis alerted clinicians to cardiovas-
cular risk associated with rosiglitazone,36 37 and to a risk
of bladder cancer with pioglitazone in 2011.38 Both side
effects have been recently ruled out,37 39 but the inﬂu-
ence of these alarms, together with weight gain, the risk
of heart failure and the increased risk of bone fractures
in women observed with this class of drugs, has limited
its use. The marginal use of GLP-1ra in our study is
similar to that of a recent study conducted in the UK,15
but in contrast with a substantial increase documented
in another region of Spain,17 Ireland and the USA.9 13
The administrative restrictions and negative economic
incentives of our institution (ICS) for the prescription of
GLP-1ar may have contributed to the limited use of this
therapeutic class. Finally, DPP4i the class of newly devel-
oped NIADs with the greatest increase in use, which is
in agreement with other reports conducted world-
wide.9 11–13 17 31–33 This rapid adoption, mainly as an
alternative to sulfonylureas, may respond to the lower
risk of hypoglycaemia, its neutral effects on body weight
and also the greater convenience of an oral treatment
instead of the need of injections for GLP-1ar or
insulin.40 In summary, although a plethora of hypogly-
caemic agents are currently available with a substantially
comparable effect in terms of glycaemic control, the
physician’s choice should be personalised based on
patient’s characteristics such as age, risk factors and
comorbidities.
When we assessed the attained glycaemic control based
on the treatment step, we found that patients on NIADs
in combination or on insulin with or without an NIAD
were the ones with the highest HbA1c levels. This is in
line with the results of several studies showing a delay in
treatment intensiﬁcation in patients already on combin-
ation therapies whose control of blood glucose remained
or became inadequate.35 41 Moreover, we found that
about half of the patients had HbA1c levels ≤7% as
recommended by clinical guidelines, about 80% below
the 8% recommended by our institution (ICS), and
about 75% below the individualised goal recommended
by the Red-GDPS. Our ﬁgures are slightly worse than the
ones reported by a study conducted in the Basque
country in Spain for patients achieving HbA1c levels
≤7% (about 64.1% of them), but similar to their 85.5%
of patients achieving a ≤8% target.42 Finally, and con-
ﬁrming previous analyses, the subgroup with the highest
proportion of patients attaining appropriate individua-
lised glycaemic control was the one of patients older than
75 years,23 while patients younger than 65 years without
comorbidities or serious complications and T2DM dur-
ation ≤15 years were less likely to achieve the correspond-
ing individualised glycaemic control target. This could be
explained by a higher proportion of obesity among
younger patients, a longer survival among adequately
controlled older patients, or by an easier to reach gly-
caemic goal in the elderly (≤8% vs ≤7%). More import-
antly, our results conﬁrm that an individualised
therapeutic approach considerably increases the chances
of attaining adequate glycaemic control and provides
effective T2DM care.43 However, one of the most striking
Figure 3 Percentage of patients
achieving glycaemic control
according to HbA1c intervals.
HbA1c, glycated haemoglobin;
T2DM, type 2 diabetes mellitus.
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ﬁndings of our study was that there were no relevant
changes across years, meaning that in spite of the overall
observed gradual increase in pharmacological treatments
along the study there was no obvious trend towards an
increase in the proportion of patients with an adequate
HbA1c target whatever the used cut-off, and the mean
HbA1c values did not signiﬁcantly change over time
regardless of the treatment step. There are few reports on
how the evolution in the prescription pattern of antidia-
betic drugs affects the level of attained glycaemic control,
but our results are in contrast with a study conducted in
Japan showing that the rate of patients achieving the
≤7% goal signiﬁcantly improved together with the pro-
gressive increase in the proportion of pharmacological
treatments.11 However, a very recent study conducted in
Canada reported that the mean HbA1c values in older
patients even increased slightly over a 5-year period in
spite of the overall increase in the use of antidiabetic
treatment.14 Our results seriously question the ICS
threshold to maintain HbA1c levels ≤8% for all patients,
giving general practitioners ﬁnancial incentives if this
goal is attained, without taking into account age, diabetes
duration or the presence of comorbidities. This threshold
was established to avoid overtreatment—especially in the
elderly—but can be counterproductive in younger
patients. Certainly, about 25% of patients had HbA1c
between 7.1% and 8%, and were therefore at
potential risk of suboptimal management or undertreat-
ment until they reached this value, especially in
people aged under 65 years. Thus, this institutional
policy potentially contributes to therapeutic inertia,
deﬁned as a delay in treatment intensiﬁcation among
patients with poor glycaemic control. Clinical inertia has
been documented in primary care settings,44 45 and a
study conducted in Catalonia in 2007 in a sample of 2783
patients with T2DM reported that therapeutic inertia was
present in 33.2% of cases, and treatment intensiﬁcation
was implemented in patients with a mean HbA1c of
8.4%,41 which is far above the 8% threshold established
by the institution. On the other hand, most family
physicians ﬁnd that patients treated with an NIAD com-
bination but needing intensiﬁcation with insulin or
GLP-1ar, and those already on insulin needing optimisa-
tion with multiple insulin doses or the addition of a
GLP-1ar, are difﬁcult to manage or they have reasonable
safety concerns. In these cases, clinical inertia is a major
factor that contributes to inadequate glycaemic control
in the long term.
Figure 4 Evolution of mean HbA1c according to the different steps of antidiabetic treatment and T2DM duration. HbA1c,
glycated haemoglobin; NIAD, non-insulin antidiabetic drug; T2DM, type 2 diabetes mellitus.
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Our results show a global negative effect of T2DM dur-
ation on glycaemic control that did not change substan-
tially across the study period. A progressive worsening of
mean Hb1Ac values within each sequential evaluation
might be expected because the proportion of patients
with a disease duration >10 years increased, but this
could have been counteracted by an intensiﬁed manage-
ment in all treatment steps, eventually leading to steady
mean HbA1c levels along the study. This is a possible
explanation if we take into account that patients in the
lowest treatment steps (ie, no drugs, and NIADs in
monotherapy or combined) and with a disease duration
>10 years had lower HbA1c values than those with a
disease duration lower than <2 years, as those on poor
glycaemic control were probably switched to the next
superior treatment step. In contrast, glycaemic control
among patients on insulin (alone or in combination)
worsened as the duration of disease increased, probably
because they are at the last treatment step and only
intensive management with multiple insulin doses under
endocrinologist supervision may improve control.
This study has strengths and limitations worth men-
tioning. The main strength is that we used a large out-
patient database that, although not completely
representative of other areas of Spain, is indicative of
the trends of general practitioners’ practices in a real-life
clinical setting. However, this was a retrospective study
subject to errors in data recording. For instance, the per-
centage of missing values for HbA1c was 35% in 2007
and decreased to 25% in 2013, although this would
apply equally to all study periods, therefore not affecting
the conclusions of the study. Moreover, we were not able
to assess whether the change in prescribed treatments
over time was driven by patients’ needs and character-
istics (eg, prior low tolerability or effectiveness), and we
cannot therefore claim a causal effect. Finally, we could
not assess whether doses were appropriately chosen, and
we did not consider data on prescriptions within the
same therapeutic class.
CONCLUSIONS
Although the intensity of pharmacological antidiabetic
treatment of T2DM increased substantially during 2007–
2013 in Catalonia, there was no evidence that this was
accompanied by a positive change in the degree of gly-
caemic control. This reveals shortcomings in the primary
healthcare system that could be tackled through more
intensive educational programmes for physicians oriented
to the individualisation of glycaemic goals and prioritising
more intensive treatments in younger patients.
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